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Background: Neurotrophic factors influence survival, differentiation, proliferation and death of neuronal cells within
the central nervous system. Human ciliary neurotrophic factor (hCNTF) has neuroprotective properties and is also
known to influence energy balance. Consequently, hCNTF has potential therapeutic applications in neurodegenerative,
obesity and diabetes related disorders. Clinical and biological applications of hCNTF necessitate a recombinant
expression system to produce large amounts of functional protein in soluble form. Earlier attempts to express
hCNTF in Escherichia coli (E. coli) were limited by low amounts and the need to refold from inclusion bodies.
Results: In this report, we describe a strategy to effectively identify constructs and conditions for soluble
expression of hCNTF in E. coli. Small-scale expression screening with soluble fusion tags identified many conditions that
yielded soluble expression. Codon optimized 6-His-hCNTF construct showed soluble expression in all the conditions
tested. Large-scale culture of the 6-His-hCNTF construct yielded high (10 – 20 fold) soluble expression (8 – 9 fold) as
compared to earlier published reports. Functional activity of recombinant 6-His-hCNTF produced was confirmed by its
binding to hCNTF receptor (hCNTFRα) with an EC50 = 36 nM.
Conclusion: Our results highlight the combination of codon optimization and screening soluble fusion tags as a
successful strategy for high yielding soluble expression of hCNTF in E. coli. Codon optimization of the hCNTF sequence
seems to be sufficient for soluble expression of hCNTF. The combined approach of codon optimization and soluble
fusion tag screen can be an effective strategy for soluble expression of pharmaceutical proteins in E. coli.
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Neurotrophic factors play central role within the nervous
system. They regulate cell survival, proliferation, differen-
tiation, migration, dendrite and axonal growth, synaptic
plasticity and interactions of neuronal and glial cells
[1-4]. The neuropoietic cytokine, ciliary neurotrophic fac-
tor (CNTF), first identified in chick ciliary neurons [5,6],
belongs to the interleukin-6 and leukemia inhibitory factor
(LIF) family of four helix bundle cytokines [7,8]. Human
CNTF (hCNTF), a polypeptide of approximate 23 kDa,
is involved in the maintenance of ciliary and motor
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unless otherwise stated.heterotrimeric complex of hCNTF receptor (hCNTFRα),
gp130 and LIF receptor (LIFRβ) [9-11]. Apart from neuro-
protection [12,13], hCNTF is also known to influence
energy balance [14-16]. Consequently, hCNTF has po-
tential therapeutic applications not only in neurodegener-
ative diseases such as Amytropic Lateral Sclerosis (ALS)
and Huntington’s disease (HD), but also in obesity and re-
lated type II diabetes. hCNTF secreting implant has com-
pleted phase II studies as an effective therapy for dry age
related macular degeneration (AMD) in the eye [17].
The therapeutic potential of CNTF necessitates a re-
combinant production system for large amounts of pro-
tein for clinical and biological applications. Bacterial
expression systems are known to be rapid and economical
for obtaining recombinant proteins [18-22]. However, at-
tempts to express hCNTF in Escherichia coli (E. coli) have
either yielded low soluble levels (approx. 13%) or insolublel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion of pharmaceutical proteins is of utmost importance
not only for direct applications but to be able to employ
advanced molecular engineering methods to alter their
physicochemical properties. Bacterial expression systems
offer several advantages; they are relatively inexpensive to
culture, can be easily modified genetically and have fast
turnaround time. E. coli, a preferred bacterial host, is con-
sidered to be a ‘laboratory workhorse’ for recombinant
protein expression. However, the advantages are easily off-
set by the challenges poised by recombinant production of
eukaryotic proteins [27,28]. Bacterial hosts such as E. coli
are often limited in amounts of tRNA for the codons that
are used rather less frequently. Instances where codon bias
of the gene is significantly different from that of the
expression host E. coli, paucity of the tRNAs severely
limits the translation process. This results in non-optimal
translation of the RNA including stalling, termination,
possible frame-shifting and low levels of protein expres-
sion [29,30]. Apart from codon usage being a determining
factor in protein expression levels, structural features of
mRNA that interfere with the initiation of translation is
also believed to adversely affect protein expression [31,32].
In contrast, a recent study found that there was very less
influence of mRNA structure on protein expression and
that depletion of charged tRNAs was the main limiting
factor for protein expression [33]. Codon optimization of
the target gene and/or use of tRNA enhanced strains have
become an attractive starting point for heterologous pro-
tein expression in E. coli. Codon optimization has been
successfully utilized to express human pigment epithelium
derived factor in E. coli [34] and thirty human short chain
dehydrogenase/reductive genes showed vast improvement
in expression with optimized codon and use of E. coli
strains containing rare codon tRNAs [35]. The other rele-
vant issue with heterologous expression in E. coli is the
formation of unordered aggregates (inclusion bodies) due
to improper folding of the polypeptide chain. High rates
of protein expression or unfavorable conditions for pro-
tein folding cause inclusion bodies formation. Successful
strategies to mitigate improper folding include decreasing
the cultivation temperature [36], co-expression of folding
modulators [37] and reducing the rate of gene expression
[38]. An alternative strategy to improve the solubility has
been to express the protein of interest fused to a solubility
enhancing polypeptide ‘tag’ [39-42]. The soluble ‘tag’ also
serves to provide a reliable translation initiation [43]. Al-
though useful, the fusion ‘tag’ strategy is limited by the
lack of a rational design for choice and a given ‘tag’ might
be effective with only certain targets [40,44-46]. In general,
production of soluble proteins in E. coli remains largely a
trial-and-error process.
In this study, we report an effective strategy towards
screening and optimization for soluble expression ofhCNTF in E. coli. We address the twin issues of codon
bias and possible improper folding by optimizing the
hCNTF gene sequence for use in E. coli and adopting a
factorial screening strategy. Small-scale screening methods
have been successful in structural genomics initiatives
[47-49] in providing reproducible qualitative and quantita-
tive leads for large-scale expression. hCNTF gene was
codon optimized and cloned into a suite of nine vectors
harboring different fusion (soluble/affinity) tags. The con-
structs were screened for expression in two different
E. coli strains and culture medias at different temperatures.
Results and discussion
The objective of our work was to achieve soluble, high
yielding production of hCNTF in E. coli. Earlier attempts
of hCNTF production in E. coli resulted in low amounts
of soluble protein or required purification from insoluble
inclusion bodies [8,23-26]. McDonald and co-workers
have reported the presence of only 13% of soluble hCNTF
in E. coli (BL21) cell extracts [23]. In another report, the
insoluble fraction from bacterial cell lysate was found to
contain 80% of recombinant hCNTF [24]. Masiakowski
et al. have also reported purifying hCNTF from inclu-
sion bodies even though the translation of recombinant
hCNTF was 20 – 40% of total protein [25]. Purification of
hCNTF from inclusion bodies requires an additional refold-
ing step and such processes are usually not desirable since
they are cumbersome and in many cases might result in
non-native state of the target protein. Non-native state of
proteins often leads to aggregation that can cause fatal im-
munogenic reactions from protein therapeutics [50]. Thus,
for proteins of pharmaceutical relevance, such as hCNTF,
it is highly desirable to have high yielding, soluble and cost
effective production of protein. An effective strategy to
express soluble proteins requires cost effective screen-
ing system where several factors could be tested in paral-
lel. Structural genomics initiatives have effectively utilized
such approaches to produce recombinant proteins in
E. coli [47-49].
In our present work, we adopted the strategy of fusing
the codon optimized sequence of hCNTF to nine tags
(eight soluble tags and the 6–His tag) and carrying out a
factorial screening for protein expression in different con-
ditions (temperature/culture media/expression strains).
The overall scheme is depicted in Figure 1. The codon op-
timized hCNTF sequence is shown in Figure 2. A propri-
etary algorithm (OptimumGene™, Genscript USA) from
the vendor was used to increase the codon usage bias in
E. coli by improving the codon adaptation index (CAI) to
0.87. GC content and unfavorable peaks were optimized
to prolong the half-life of the mRNA. Stem-loop struc-
tures that have an impact on ribosomal binding and stabil-
ity of mRNA, were disrupted. In addition, the codon
optimization process screened and successfully modified
Figure 1 Scheme depicting the overall strategy of parallel cloning, small-scale expression screening and large-scale hCNTF production.
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family of vectors have been described elsewhere [51-53].
Each vector has a N-terminal fusion ‘tag’ (Table 1) followed
by Rhinovirus 3C protease cleavage site between the ‘tag’
and the inserted target sequence to facilitate ‘tag’ removal.
The set of vectors have common cloning sites (KpnI
and HindIII) that facilitate parallel cloning and con-
struction of expression vectors. A cloning efficiency of
100% was achieved by picking three clones for each vector
construction. The constructs were transformed into E. coli
strains, BL21(DE3)pLysS and Rosetta 2(DE3)pLysS (a de-
rivative of BL21 supplying tRNAs for 7 rare codons; AGA,
AGG, AUA, CUA, GGA, CCC, and CGG) and small-scale
expressions were carried out with culture medias Power
Prime Broth (PPB) at 20°C/37°C and Overnight Expression
Terrifc Broth (TBONEX) at 25°C.
The soluble fusion tags used in expression screening
are listed in Table 1. The choice of soluble tags has been
dictated by literature precedence on the success rate of
soluble expression of a diverse set of proteins. No single
soluble tag can increase the expression and solubility of
all target proteins. However, some general trends oneffectiveness of a limited set of tags (amongst those used
in present study) have been reported in some studies.
SUMO and NusA were found to be equally efficient in
terms of total and soluble protein expression in studies
on three model proteins [41,45]. The success of a par-
ticular soluble fusion tag is dependent on the target pro-
tein of interest and hence the need to screen a diverse
set. Both the culture medias used, PPB and TBONEX,
are rich and support high cell densities. TBONEX, being
an auto-induction media, also offers the advantage of a
simplified expression protocol by eliminating the moni-
toring and induction steps. Induction free protocol is
particularly useful for high-throughput protein expres-
sion approaches. Culture growth in PPB was screened at
temperatures 20°C and the normal 37°C. Lower culture
temperature is known to facilitate proper folding and
soluble protein expression [36].
The soluble fractions were treated with Ni-NTA
magnetic beads to capture recombinant 6-His-(fusion
tag)-hCNTF proteins. The eluted soluble, Ni-NTA af-
finity purified fractions were analyzed on a SDS-PAGE gel
(Figure 3).
10 30 60
wt     ATGGCGTTTACCGAACATAGCCCGCTGACCCCGCATCGCCGCGATCTGTGCAGCCGCAGC
co     ATGGCGTTTACCGAACATTCCCCGCTGACCCCGCATCGTCGTGACCTGTGTAGTCGCTCA
aa     M  A  F  T E  H  S  P  L  T  P  H  R  R  D L  C  S  R  S 
70        90              120
wt     ATTTGGCTGGCGCGCAAAATTCGCAGCGATCTGACCGCGCTGACCGAAAGCTATGTGAAA
co     ATCTGGCTGGCTCGCAAAATCCGCTCCGATCTGACCGCCCTGACGGAATCATATGTTAAA
aa I  W  L  A  R  K  I  R  S  D  L  T  A  L  T  E  S  Y  V  K 
130       150              180
wt     CATCAGGGCCTGAACAAAAACATTAACCTGGATAGCGCGGATGGCATGCCGGTGGCGAGC
co     CATCAGGGCCTGAACAAAAATATTAACCTGGATTCGGCAGACGGTATGCCGGTCGCTAGC
aa      H  Q  G  L  N  K  N  I  N  L  D  S  A  D  G  M  P  V  A  S 
190       210       240
wt     ACCGATCAGTGGAGCGAACTGACCGAAGCGGAACGCCTGCAGGAAAACCTGCAGGCGTAT
co     ACCGACCAGTGGTCTGAACTGACGGAAGCGGAACGTCTGCAGGAAAATCTGCAAGCCTAC
aa     T  D  Q  W  S  E  L  T  E  A  E  R  L  Q  E  N  L  Q  A  Y 
250       270       300
wt     CGCACCTTTCATGTGCTGCTGGCGCGCCTGCTGGAAGATCAGCAGGTGCATTTTACCCCG
co     CGTACCTTTCATGTCCTGCTGGCACGCCTGCTGGAAGATCAGCAAGTGCACTTTACCCCG
aa     R  T  F  H  V  L  L  A  R  L  L  E  D  Q  Q  V  H  F  T  P 
310       330       360
wt     ACCGAAGGCGATTTTCATCAGGCGATTCATACCCTGCTGCTGCAGGTGGCGGCGTTTGCG
co     ACGGAAGGCGACTTCCATCAGGCTATCCACACGCTGCTGCTGCAGGTGGCAGCATTCGCG
aa     T  E  G  D  F  H  Q  A  I  H  T  L  L  L  Q  V  A  A  F  A
370       390       420
wt     TATCAGATTGAAGAACTGATGATTCTGCTGGAATATAAAATTCCGCGCAACGAAGCGGAT
co     TATCAAATTGAAGAACTGATGATCCTGCTGGAATACAAAATTCCGCGCAATGAAGCGGAT
aa     Y  Q  I  E  E  L  M  I  L  L  E  Y  K  I  P  R  N  E  A  D 
430       450       480
wt     GGCATGCCGATTAACGTGGGCGATGGCGGCCTGTTTGAAAAAAAACTGTGGGGCCTGAAA
co     GGCATGCCGATCAACGTTGGTGACGGCGGTCTGTTTGAGAAAAAACTGTGGGGTCTGAAA
aa     G  M  P  I  N  V  G  D  G  G  L  F  E  K  K  L  W  G  L  K 
490       510       540
wt GTGCTGCAGGAACTGAGCCAGTGGACCGTGCGCAGCATTCATGATCTGCGCTTTATTAGC
co     GTGCTGCAGGAACTGAGTCAATGGACCGTTCGTTCCATTCACGATCTGCGCTTCATCTCT
aa     V  L  Q  E  L  S  Q  W  T  V  R  S  I  H  D  L  R  F  I  S 
550       570       600
wt     AGCCATCAGACCGGCATTCCGGCGCGCGGCAGCCATTATATTGCGAACAACAAAAAAATG
co     TCACATCAGACGGGTATTCCGGCTCGTGGCTCGCACTACATCGCAAACAACAAGAAGATG
aa     S  H  Q  T  G  I  P  A  R  G  S  H  Y  I  A  N  N  K  K  M 
Figure 2 Comparison of wild type (wt) and codon optimized (co) hCNTF sequence.
Table 1 Expression vectors and their fusion tags













1 pOPINF 6-His- 1 1 1 1 1 1
2 pOPINS3C 6-His-SUMO- 0.7 1.5 2.1 1.3 2.7 1.1
3 pOPINTRX 6-His-Thioredoxin- 1.2 1.7 4.9 1.1 0.7 0.1
4 pOPINMSYB 6-His-MsyB- 0.5 0.8 2.9 1.8 3.6 2.0
5 pOPINJ 6-His-GST- 0.3 1.3 0.4 0.1 0.5 0.1
6 pOPINHALO7 6-His-Halo- 1.5 1.6 1.7 1.6 3.0 2.0
7 pOPINM 6-His-MBP- 0.8 1.4 2.5 0.9 1.1 0.7
8 pOPINTF 6-His-Trigger Factor- 0.5 1.1 1.7 0.3 0.6 0.5
9 pOPINNusA 6-His-NusA- 0.6 1.2 1.1 0.7 0.8 0.1
Empirical scores of soluble fraction yield in small-scale expression relative to 6-His-construct. Highlighted text in bold within the vector name symbolize the fusion tag.
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Figure 3 SDS-PAGE analysis of small-scale expression screen. (a) BL21/PPB/20°C; (b) BL21/PPB/37°C; (c) BL21/TBONEX/25°C; (d) Rosetta 2/
PPB/20°C; (e) Rosetta 2/PPB/37°C; (f) Rosetta/TBONEX/25°C. Lanes M, 1–9 denote protein marker and Ni-NTA purified soluble hCNTF fusion
constructs from expression vectors as listed in Table 1, respectively. The gel was stained with Coomassie Blue dye.
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for expression showed the presence of soluble hCNTF as
fusions (Figures 3 and 4). On an average, the percentage
of hCNTF in the soluble fraction was close to 80% or
more in majority of the conditions screened. RelativeFigure 4 Histograms depicting percentage soluble fraction of hCNTF
37°C; (c) BL21/TBONEX/25°C; (d) Rosetta 2/PPB/20°C; (e) Rosetta 2/PPB/37°C
from three technical repeats.amounts of soluble hCNTF as fusions with soluble tags
were empirically estimated (comparing intensity of bands)
with respect to the 6-His-construct in each experimental
condition (Table 1). The intensity of the bands depends
on protein concentration and also on the size and contentin small-scale expression screen. (a) BL21/PPB/20°C; (b) BL21/PPB/
; (f) Rosetta/TBONEX/25°C. The estimates are based on measurements
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not normalized against molecular size and residue con-
tent and as such the scores should not be used for direct
comparisons but for easy visual summarization of relative
trends. The efficacies of the fusion tags (scores averaged
over the six expression conditions) were ranked as com-
pared to the 6-His- tag. The trend observed was in the
order of MsyB/Halo (1.9-fold); SUMO/Trx (1.6-fold);
MBP/TF/NusA (approx. 1-fold) and GST (0.5 fold). Signifi-
cant proteolysis seems to have taken place for some of the
larger fusions (Figure 3; Halo, MBP, TF). This could pos-
sibly be due to improper folding of the larger fusion con-
structs. In a recent publication [53], Bird has reported
similar observations with the larger fusion constructs. The
most significant observation of our small scale screening
experiment was that under all conditions, 6-His-hCNTF
constructs showed appreciable amounts of expression. It
is highly desirable to obtain soluble expression of proteins
without a solubility enhancing fusion partner as the down-
stream purification process can avoid additional steps of
tag cleavage and protease removal. Also, some proteins
might exhibit markedly low solubility after the fusion tag
has been cleaved off; limiting the utility of soluble fusion
tags in such cases. The 6-His-tag is merely an affinity tag
for purification and in all probability does not improve the
solubility of recombinant hCNTF as such, unlike the other
fusion tags. In fact, in a study on 20 human proteins, the
6-His-tag had a negative impact on protein solubility
when present at either the N- or C-terminus [54]. In this
context, our results for soluble expression of 6-His-
hCNTF assume significant importance. Assuming that the
6-His-tag does not influence the solubility of recombinant
hCNTF, or at least in a positive way, the soluble expres-
sion of hCNTF in the conditions tested can be attributed
to codon optimization of the hCNTF sequence. Our ex-
perimental design was aimed at maximizing the chances
of obtaining soluble protein in the backdrop of literature
precedence [23-26]. However, we do note that in earlier
published reports [23-26] of recombinant expression in
E. coli with the wild type hCNTF; conditions of expression
as varied as in our experimental set up (soluble fusion
tags, lower temperatures and expression strain rich in
tRNAs for rare codons) were not explored. Results from
the earlier studies hint at the fact that most probably both
translation (low yields of 5–10 mg/L) and folding (inclu-
sion body formation) were the limiting factors in expres-
sion. It might thus be of interest to see the outcome of
recombinant expression of the wild type sequence in a
strain rich in tRNAs for rare codons, such as Rosetta 2
(DE3) or as a fusion construct with soluble tags in a strain,
such as BL21(DE3). Even if the results of such experi-
ments were positive, the codon optimized sequence used
in the present study clearly results in a vast improvement
since it allows high yielding soluble expression in BL21at 37°C (approx. 90% or more in soluble fraction) without
the aid of soluble fusion tags in contrast to the wild
type sequence under similar conditions in previous
studies [23-26]. With easy and cheap availability of syn-
thetic genes, the optimized hCNTF codon sequence pre-
sents an ideal option for recombinant production in BL21
(a common laboratory strain) without the need for a sol-
uble fusion tag.
Results from small-scale expression show varying effi-
cacies of the fusion constructs in different conditions of
growth as determined empirically (Table 1). However,
since the overall yield after the cleavage of the fusion tag
and purification might be very different from that of the
fusion construct and also the need for additional tag
cleavage and removal steps; 6-His-hCNTF was chosen
for large scale expression with Rosetta 2(pLysS) and the
auto inducing media, TBONEX at 25°C as a representative
example. The analysis of the overall purification scheme is
shown in Figure 5.
The amount of hCNTF protein obtained after final purifi-
cation was 112 mg/L of culture. This is a vast improvement
(greater than 10 – 20 fold) in overall yield from earlier re-
ports of 5 – 10 mg/L [23,24]. Functional activity of recom-
binant hCNTF was confirmed by binding to hCNTFRα
(Figure 6). The binding showed an EC50 value of 36 nM in
accordance with an earlier published report [55]. A very
recent report [56] published during the course of this
manuscript preparation, has highlighted an attractive al-
ternate strategy to express high yielding soluble hCNTF in
E. coli. The study reports the usage of a single protein pro-
duction (SPP) system that co-expresses E. coli toxin
mRNA interferase, MazF and hCNTF. The strategy targets
down-regulating the expression of endogenous bacterial
proteins by selectively cleaving the ACA sites in host
mRNAs by MazF. The hCNTF gene sequence was opti-
mized for codon usage in E. coli and removing the ACA
sites. So, whereas in the recently published study, a codon
optimization strategy was directed at more specific use
with the expression system, in our present study, a more
sophisticated proprietary codon optimization algorithm
OptimumGene™ (GenScript, NJ, USA) was used. hCNTF
codons in our present study were not only optimized for
codon usage in E. coli but parameters such as GC content,
CpG dinucleotides content, mRNA secondary structure,
cryptic splicing sites, premature PolyA sites, internal chi
sites and ribosomal binding sites, negative CpG islands,
RNA instability motif, repeat sequences were also opti-
mized. The SPP system seems to be a promising approach,
however, its robustness as a general strategy needs to be
validated for a number of proteins. It appears that the SPP
system might be useful in obtaining high yields of recom-
binant proteins indirectly by suppressing endogenous pro-
tein expression. However, protein sequences that might
not fold properly once translated might still need soluble
Figure 5 SDS-PAGE analysis of recombinant 6-His-hCNTF
purification. M: protein marker; 1: crude cell lysate; 2: soluble fraction;
3: Ni-IDA purified hCNTF; 4: size exclusion chromatography purified
hCNTF. The gel was stained with Coomassie Blue dye.
Figure 6 Binding of biotinylated hCNTF to hCNTFRα.
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approach to screen with a suite of soluble tags might
have a more versatile utility. It would be interesting to in-
tegrate our approach (a sophisticated codon optimization
and screening with soluble tags in different strains of
E. coli) with the SPP system (down-regulating endogen-
ous bacterial proteins) for enhanced expression of difficult
eukaryotic targets.Conclusions
We report here high yielding soluble expression of func-
tional hCNTF in E. coli. Our combined approach of codon
optimization and screening for soluble expression with
nine fusion tags under varying culture conditions identi-
fied several constructs producing soluble hCNTF expres-
sion (8 – 9 fold higher soluble fraction) and the overall
yield of purified recombinant hCNTF achieved was signifi-
cantly higher (greater than 10 – 20 fold) as compared
to previous published reports. Soluble expression of the
6-His-hCNTF in all conditions tested points to the fact
that codon optimization is sufficient for soluble expression
of hCNTF in E. coli. However, for maximal yields, some
fusion constructs might be more useful than 6-His-
hCNTF. The strategy of combining codon optimization
and fusion tag screening might be useful for soluble ex-
pression of pharmaceutical proteins in E. coli.Methods
Codon optimization
The codons of the hCNTF gene were optimized for opti-
mal usage in E. coli using a commercial proprietary algo-
rithm, OptimumGene™ (GenScript, NJ, USA). Variety of
parameters were optimized, including codon usage bias,
GC content, CpG dinucleotides content, mRNA second-
ary structure, cryptic splicing sites, premature PolyA sites,
internal chi sites and ribosomal binding sites, negative
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synthetic gene was purchased from GenScript, US.
Construction of expression vectors
The construction of pOPIN-fusion vector backbones has
been described elsewhere [51-53]. The complete coding
sequence of hCNTF was synthesized by GenScript, NJ,
USA and provided as an insert within pUC57 plasmid.
hCNTF gene was amplified by polymerase chain reaction
(PCR) using KOD Hot Start (Novagen) with primers that
had 5’-extensions of AAGTTCTGTTTCAGGGCCCG
and ATGGTCTAGAAAGCTTTA on the forward and re-
verse primers, respectively (Additional file 1: Figure S1).
The set of nine vectors harboring various fusion tags is
listed in Table 1. The purified PCR product was inserted
into digested pOPIN vectors between KpnI and HindIII
restriction sites using Gibson Assembly™ cloning kit (New
England Biolabs, MA, USA) and the reaction mixture
transformed into NEB 5α (New England Biolabs, MA,
USA) competent cells. Three colonies were screened
for each construct and the presence of insert verified by
PCR using a vector specific forward primer and hCNTF
gene specific reverse primer (Additional file 1: Figure S2).
pOPIN expression vectors 6-His-(fusion tag)-hCNTFs ob-




Small-scale expression, affinity purification for soluble
protein characterization
Expression strains BL21 (DE3)pLysS (Novagen) and
Rosetta 2(DE3)pLysS (Novagen) were transformed with
expression plasmids. Single colonies were used to inocu-
late 0.7 ml Power Prime Broth, PPB (AthenaEs) supple-
mented with ampicillin (100 μg/ml) and chloramphenicol
(34 μg/ml) taken in a 2 ml 96-well plate. The plates were
sealed with gas permeable adhesive seals and the seed cul-
tures grown overnight at 37°C with shaking at 250 rpm.
For the small-scale expression screen, 150 μl of BL21
(DE3)pLysS and 250 μl of Rosetta 2(DE3)pLysS seed cul-
tures were used to inoculate 3 ml of PPB and Overnight
Express™ Instant TB media, TBONEX (Novagen) taken in
a 10 ml 24-deepwell plate and supplemented with ampicil-
lin (100 μg/ml) and chloramphenicol (34 μg/ml). Cultures
in PPB were grown at 37°C with shaking at 250 rpm.
For expression at 37°C, 1 mM IPTG was added when the
OD600 reached between 0.5 - 0.6. For expression at 20°C,
the cultures were cooled for 15 minutes on a bench top
before adding 1 mM IPTG and grown at 20°C overnight
(18 h) with shaking at 250 rpm. TBONEX auto-inducing
cultures were grown at 25°C for 24 h with shaking at
225 rpm. The cultures were harvested by centrifugation
and the supernatant removed from the pellets. The pelletswere stored at −80°C. The frozen pellets were resuspended
in 210 μL of 50 mM NaH2PO4, 300 mM NaCl, pH 8.0;
10 mM imidazole, 1 mM dithiothreitol (DTT), protease
inhibitor cocktail, PIC (Sigma). The pellets were freeze-
thawed three times; resuspending each time in between
the freeze thaw cycle. 1 μL of Lysonase (EMD Millipore)
was added to each pellet suspension and incubated at
room temperature with shaking at 270 rpm for 45 minutes.
The lysates were then centrifuged at 21,100 g at 4°C for
40 minutes. 20 μL of suspended nickel nitriloacetic
(Ni-NTA) magnetic beads (GenScript, NJ, USA) was dis-
pensed into each well of a 96-well flat bottom plate. The
beads were conditioned with 50 mM NaH2PO4, 300 mM
NaCl, pH 8.0; 10 mM imidazole, 1% Tween 20. Superna-
tants from cleared lysates were transferred to the wells
containing the magnetic beads and incubated at room
temperature for 50 minutes with shaking at 270 rpm. The
plate was then placed on a magnetic rack (New England
Biolabs, MA, USA) for 5 minutes and the supernatant was
removed. The magnetic beads were washed four times
with 50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 20 mM
imidazole, 0.05% Tween 20 and 1 mM DTT. Proteins
bound to the magnetic beads were eluted by adding 50 μL
of 50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 250 mM
imidazole, 0.05% Tween 20 and 1 mM DTT and incubat-
ing with shaking (270 rpm) at room temperature for
10 minutes. The plate was placed on the magnetic rack
for 7 minutes and 45 μL of the supernatant was removed.
Protein samples were heated at 95°C with SDS-PAGE
sample buffer and analyzed on a SDS-PAGE gel. The 6-
His-fusion constructs of hCNTF were verified by specific
detection of the 6-His tag using Pierce 6XHis protein tag
stain reagent set (Thermo Fisher Scientific Inc., USA).
Estimation of soluble fraction of total recombinant
protein expressed
Cell pellets from 3 ml expression culture were thawed and
resuspended in 250 μL of 50 mM NaH2PO4, 300 mM
NaCl pH 8.0; 0.2% Tween 20. The pellets were freeze-
thawed three cycles and 50 μL of the suspended pellets
were each treated with 1 μL of Lysonase. The pellets were
incubated at room temperature for 45 minutes with shak-
ing at 270 rpm. The mixture was divided into two frac-
tions of 25 μL each. For total protein samples, 25 μL of
the cell suspension was diluted with an equal volume of
water followed by 10 μL of 6X SDS-PAGE sample buffer
and boiled for 15 minutes at 95°C. The samples were cen-
trifuged at high speed for 15 minutes and the supernatant
run as the ‘total protein’ sample on a SDS-PAGE gel. For
the soluble fraction, the 25 μL cell suspension was diluted
with an equal volume of water and centrifuged at high
speed for 15 minutes. The supernatant was removed and
mixed with 10 μL of 6X denaturing SDS-PAGE sample
buffer and boiled for 15 minutes at 95°C. The samples
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GelQuant.NET software (V 1.7.8) from biochemlabsolu-
tions.com was used to quantitate band intensities to esti-
mate the ratio of soluble to total protein. The values were
averaged over three measurements. The intensity esti-
mates for comparisons between constructs should be re-
stricted to samples run within the same gel.
Large-scale expression and purification of hCNTF
6-His-hCNTF construct was chosen for large scale expres-
sion in Rosetta 2 (DE3)pLysS with the auto-inducing
media TBONEX. 2 X 450 ml of cultures were inoculated
with overnight seed cultures (30:1) and grown at 25°C
with shaking at 270 rpm for 30 h. The cells were harvested
by centrifugation at 10,000 g for 30 minutes at 4°C. and
frozen at −80°C. The cell pellet was resuspended in lysis
buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM
imidazole, 1 mM DTT and PIC) and freeze thawed three
cycles, resuspending thoroughly after thawing each time.
Lysonase was added to the suspension and incubated at
room temperature for 60 minutes with gentle agitation.
The lysate was centrifuged at 14,500 g at 4°C for 50 mi-
nutes and the cleared supernatant incubated with Ni-IDA
resin (Macherey Nagel) at 4°C for 120 minutes with gentle
agitation. The supernatant was removed by centrifugation
at 500 g for 3 minutes and the Ni-IDA resin washed with
50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM imid-
azole, 1 mM DTT and PIC. In subsequent washes, the
imidazole concentration was increased. Bound hCNTF
was eluted out of the resin (Additional file 1: Figure S3) by
adding 250 mM imidazole to the buffer and the eluted
fractions pooled, concentrated and buffer exchanged in
100 mM NaH2PO4, 300 mM NaCl, pH 8.0; 1 mM DTT
using Amicon® Ultra-4 centrifugal filter units with a
3 kDa molecular weight cut off (Merck Millipore).
The Ni-IDA eluted protein was further purified by
size exclusion chromatography (SEC) by loading onto
a HiLoad Superdex 200 prep grade filtration column
(Additional file 1: Figure S4). The protein fractions were
pooled, concentrated and buffer exchanged in 100 mM
NaH2PO4, 50 mM NaCl, pH 8.0; 2 mM DTT using centri-
fugal filter units.
Binding assay of biotinylated hCNTF with hCNTFRα
hCNTF was labeled with biotin for binding studies with
hCNTFRα. Briefly, hCNTF was reacted with a 20-fold
molar excess of NHS-PEG4-biotin in a 100 mM carbon-
ate buffer solution for 2 h at room temperature with
gentle agitation. The reaction mixture was buffer ex-
changed with 100 mM NaH2PO4, 50 mM NaCl, pH 8.0
and concentrated using a spin filter having 3 kDa mo-
lecular weight cut off.
For the binding study, 1 μg of hCNTFRα (Sino Biologicals
Inc.) in PBS was immobilized on the surface of a NuncMaxiSorp flat-bottomed 96-well plate. The wells were
washed with 50 mM Tris–HCl, 150 mM NaCl, 0.05%
Tween 20, pH 7.0 (TBS-T) and blocked with a 2% BSA in
TBS-T solution. After washings, biotinylated CNTF was
added in varying amounts (0.2 – 3.0 μg) to the wells and
incubated at room temperature for 2 h with gentle agita-
tion. The wells were then washed with TBS-T followed by
the addition of 50 ng of HRP (horseradish peroxidase)-
conjugated streptavidin (Thermo Scientific) to each well
and incubated at room temperature for 70 minutes with
gentle agitation. The wells were washed and 200 μL of
TMB (3,3’, 5,5’-tetramethylbenzidine; Thermo Scientific)
was added to each well. The reaction was stopped with
2 M H2SO4 and the optical density measured at 450 nm
using a spectrophotometer (Varioskan Flash; Thermo
Scientific).
Availability of supporting data
The data set supporting the results of this article are in-
cluded within the article and in Additional file 1.
Additional file 1: Figures S1 - S4. Description: PCR
amplified hCNTF, validation of hCNTF clones in expres-
sion vectors, affinity batch purification fractions, size ex-
clusion chromatography profile.
Endnote
aDuring the course of this manuscript preparation, an
alternate expression system expressing soluble hCNTF
in E. coli was published. This has been discussed in the
‘Results and Discussion’ section.
Additional file
Additional file 1: Figure S1. PCR-amplified hCNTF insert. Table S1 PCR
primers for the amplification of the synthesized hCNTF. Figure S2 PCR
validation of cloned hCNTF in pOPIN vectors. Figure S3 Representative
eluted fractions from Ni-IDA batch purification of 2 × 450 ml cultures
(A and B). Figure S4 Size exclusion chromatography (SEC).
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